BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ENJAYMO (sutimlimab-jome) by Recordati is classical complement pathway inhibitors [moa]. First approved in 2022.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENJAYMO (sutimlimab-jome) is a classical complement pathway inhibitor administered by injection, approved in February 2022. It works by blocking the C1s enzyme in the complement cascade to prevent hemolysis and related complications. The drug targets patients with rare hemolytic conditions driven by classical complement activation.
$0.001BPart D
PeakProduct is at peak commercial stage with modest Part D utilization (70 claims in 2023), suggesting a niche indication with limited but stable patient population supporting specialized commercial infrastructure.
Mechanism of Action
Classical Complement Pathway Inhibitors
Pharmacologic Class:
Classical Complement Pathway Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENJAYMO roles are not currently showing linked job postings, but peak-stage rare disease biologics typically require specialized commercial and medical affairs teams fluent in niche disease management and payer negotiation. Career value lies in rare disease expertise and complement biology knowledge rather than scale.
Brand Manager
Worked on ENJAYMO at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.